There were 464 press releases posted in the last 24 hours and 150,598 in the last 365 days.

IMPORTANT OVASCIENCE, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors…

Lead Plaintiff Deadline is January 22, 2018    

NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired OvaScience, Inc. (NASDAQ:OVAS) (“OvaScience or the “Company”) securities traceable to the January 8, 2015 Secondary Public Offering (the “Offering”).   

Investors who have incurred losses in OvaScience, Inc. are urged to contact the firm immediately at or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website,

If you have incurred losses in the securities of OvaScience, Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no later than January 22, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in OvaScience, Inc.

OvaScience is a life science company that engages in the discovery, development, and commercialization of new treatments for infertility. The Company is attempting to develop various fertility treatment options purported to enhance egg health and revolutionize in vitro fertilization (“IVF”). The Company’s Autologous Germline Mitochondrial Energy Transfer (“AUGMENT”) treatment, designed to improve the energy and health of the woman’s eggs by using mitochondria from a woman’s egg precursor cells (“EggPCs”), is available in certain IVF clinics in select international regions.

According to the field complaint, Defendants violated provisions of the Securities Act by issuing false and misleading statements to investors, including in filings with the U.S. Securities and Exchange Commission (“SEC”).

/EIN News/ -- Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:

  • the very science behind AUGMENT was untested and in doubt;
  • the patients that had received OvaScience’s AUGMENT procedure in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without the Company’s AUGMENT procedure;

    the Company had not chosen to undertake its studies outside of the United States, but was forced to as it did not want to meet stringent and expensive federal regulations; and 

  • the Company was far from being profitable, or even approaching profitability.

Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at, or visit our website at

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##


Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email:, or
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Primary Logo

Distribution channels: Consumer Goods, Law

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.